TriSalus PEDD Method Increases Microsphere Penetration in Liver Tumors, Study Highlights New Delivery Approach
Portfolio Pulse from Benzinga Newsdesk
TriSalus Life Sciences (NASDAQ:TLSI) has published research demonstrating that its Pressure-Enabled Drug Delivery (PEDD) method significantly improves the delivery of glass microspheres into liver tumors compared to conventional methods. The study, conducted on a porcine liver tumor model, shows enhanced penetration and potential for more effective cancer treatment.
September 23, 2024 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TriSalus Life Sciences' PEDD method shows significant improvement in delivering glass microspheres into liver tumors, potentially enhancing cancer treatment efficacy. This could positively impact TLSI's stock as it highlights a breakthrough in their technology.
The study highlights a significant advancement in TriSalus' PEDD method, showing improved delivery of therapeutics into liver tumors. This breakthrough could enhance the company's reputation and market position, likely leading to a positive short-term impact on TLSI's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100